



4 #4 03C0
Patent Application
Attorney Docket No. PC11843ATMC

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this 1st day of April 2002.

By

Kelley D. Surprenant
(Signature of person mailing)
Kelley D. Surprenant

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Robert Rosati :

APPLICATION NO.: 10/056,397 : Examiner: To be assigned

FILING DATE: January 23, 2002 : Group Art Unit: To be assigned

TITLE: Method of Treating Certain Cancers Using an :
Estrogen Agonist /Antagonist

Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicants herein make available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820, which lists the references, cited by the applicant, copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Respectfully submitted,

Date:

4/1/2002

Todd M. Crissey

Todd M. Crissey
Attorney for Applicant(s)
Reg. No. 37,807

Pfizer Inc.
Patent Department, MS 1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-4331